IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
PACIFIC Trial: Adjuvant Immunotherapy Improves Overall Survival (OS) in Stage III NSCLC – BTOG | British Thoracic Oncology Group
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
PDF) PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - Annals of Oncology
Immunotherapy: once more at the cutting edge of progress - memoinOncology
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
Immunotherapy in Advanced Lung Cancer
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
Exploratory 3-year overall survival for patients with unresectable... | Download Scientific Diagram
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
First-line Durvalumab Improves Survival
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
